Singapore markets closed

Fulcrum Therapeutics, Inc. (FULC)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
9.44-0.02 (-0.21%)
As of 09:49AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close9.46
Open9.48
Bid9.34 x 200
Ask9.53 x 200
Day's range9.41 - 9.50
52-week range2.25 - 13.70
Volume6,277
Avg. volume705,314
Market cap584.668M
Beta (5Y monthly)2.30
PE ratio (TTM)N/A
EPS (TTM)-1.59
Earnings date13 May 2024 - 17 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est13.25
  • GlobeNewswire

    Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to Patrick Horn, M.D., Ph.D., the company’s newly appointed chief medical officer. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the co

  • GlobeNewswire

    Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer

    ―Industry veteran with late-stage clinical development, medical affairs, and regulatory experience; well-positioned to advance losmapimod towards a potential regulatory submission and approval ― ― Interim Chief Medical Officer, Iain Fraser, MBChB, DPhil, will continue to serve on Fulcrum’s executive leadership team as senior vice president (SVP) of early development ― CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage bioph

  • Simply Wall St.

    CEO, President & Director of Fulcrum Therapeutics Alexander Sapir Buys More Stock

    Investors who take an interest in Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) should definitely note that the CEO...